A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

Exclusion Criteria

• •Previous treatment with a RAS inhibitor
• •Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-4001
• •Received prior palliative radiation within 14 days of Cycle 1, Day 1
• •Have primary central nervous system (CNS) tumors
• •Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
• •Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
• •Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial